Literature DB >> 25589999

Buyer beware: understanding the assumptions behind health economic assessments in personalized cancer care.

D Ross Camidge1, Adam J Atherly1.   

Abstract

Entities:  

Year:  2014        PMID： 25589999      PMCID： PMC4283326          DOI： 10.3978/j.issn.2072-1439.2014.12.41

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  11 in total

1.  Cost effectiveness of EML4-ALK fusion testing and first-line crizotinib treatment for patients with advanced ALK-positive non-small-cell lung cancer.

Authors:  Sandjar Djalalov; Jaclyn Beca; Jeffrey S Hoch; Murray Krahn; Ming-Sound Tsao; Jean-Claude Cutz; Natasha B Leighl
Journal:  J Clin Oncol       Date:  2014-02-24       Impact factor: 44.544

2.  Cost-effectiveness of treatment of childhood acute lymphoblastic leukemia with chemotherapy only: the influence of new medication and diagnostic technology.

Authors:  Raphaële R L van Litsenburg; Carin A Uyl-de Groot; Hein Raat; Gertjan J L Kaspers; Reinoud J B J Gemke
Journal:  Pediatr Blood Cancer       Date:  2011-05-25       Impact factor: 3.167

3.  Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer.

Authors:  Jeong-Ok Lee; Tae Min Kim; Se-Hoon Lee; Dong-Wan Kim; Soyeon Kim; Yoon-Kyung Jeon; Doo Hyun Chung; Woo-Ho Kim; Young Tae Kim; Seok-Chul Yang; Young Whan Kim; Dae Seog Heo; Yung-Jue Bang
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

4.  Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.

Authors:  D Ross Camidge; Scott A Kono; Xian Lu; Sonia Okuyama; Anna E Barón; Ana B Oton; Angela M Davies; Marileila Varella-Garcia; Wilbur Franklin; Robert C Doebele
Journal:  J Thorac Oncol       Date:  2011-04       Impact factor: 15.609

5.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

8.  Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Authors:  Alice T Shaw; Dong-Wan Kim; Kazuhiko Nakagawa; Takashi Seto; Lucio Crinó; Myung-Ju Ahn; Tommaso De Pas; Benjamin Besse; Benjamin J Solomon; Fiona Blackhall; Yi-Long Wu; Michael Thomas; Kenneth J O'Byrne; Denis Moro-Sibilot; D Ross Camidge; Tony Mok; Vera Hirsh; Gregory J Riely; Shrividya Iyer; Vanessa Tassell; Anna Polli; Keith D Wilner; Pasi A Jänne
Journal:  N Engl J Med       Date:  2013-06-01       Impact factor: 91.245

9.  Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

Authors:  D Ross Camidge; Yung-Jue Bang; Eunice L Kwak; A John Iafrate; Marileila Varella-Garcia; Stephen B Fox; Gregory J Riely; Benjamin Solomon; Sai-Hong I Ou; Dong-Wan Kim; Ravi Salgia; Panagiotis Fidias; Jeffrey A Engelman; Leena Gandhi; Pasi A Jänne; Daniel B Costa; Geoffrey I Shapiro; Patricia Lorusso; Katherine Ruffner; Patricia Stephenson; Yiyun Tang; Keith Wilner; Jeffrey W Clark; Alice T Shaw
Journal:  Lancet Oncol       Date:  2012-09-04       Impact factor: 41.316

10.  The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers.

Authors:  A J Atherly; D R Camidge
Journal:  Br J Cancer       Date:  2012-02-28       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.